David Fajgenbaum, MD, MBA, MSc, cofounder of Every Cure, shared that the organization is able to reduce clinical trial costs to $1 to $5 million per drug trial, and that clinical trials are not always necessary to expand a drug's indication.
In this installment of the "Expanding Horizons" series, David Fajgenbaum, MD, MBA, MSc, cofounder of Every Cure and physician scientist at the University of Pennsylvania, explains the logistics of expanding rare disease drug access and financial considerations in clinical trials.
Fajgenbaum expresses excitement about significantly reducing the cost of trials for repurposed drugs to between $1 and $5 million, in contrast to the substantial amounts spent by drug companies on developing new drugs. According to research published in JAMA Health Forum, the National Institutes of Health spent an average of $33.8 million per FDA-approved drug between 2010 and 2019, including $13.9 million per drug for phase 1 trials, $22.2 million per drug for phase 2 trials, and $12.9 million per drug for phase 3 trials. The cost reductions by Every Cure are seen as a key element in making drug repurposing more feasible.
He also addresses insurance challenges, including the issue of setting different prices for the same drug with different indications, and discusses ongoing conversations with insurers. The goal is to pick trials strategically, where successful outcomes would economically make sense for insurers to cover the drug.
“It's all coming together right now,” Fajgenbaum said. “Frankly, we should have been doing this for a long time, but there's no time that's better than now.”
Check out part 1 and part 2 of the "Expanding Horizons" feature series. To learn more about Every Cure's work toward increasing rare disease treatments, visit www.everycure.org
Reference
Zhou EW, Jackson MJ, Ledley FD. Spending on phased clinical development of approved drugs by the US National Institutes of Health compared with industry. JAMA Health Forum. 2023;4(7):e231921. doi:10.1001/jamahealthforum.2023.1921
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD
May 2nd 2024Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.
Read More
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More